Potential diagnostic biomarkers of Ulcerative Colitis-associated colorectal dysplasia by Merli, Angela-Maria et al.
POTENTIAL DIAGNOSTIC BIOMARKERS OF ULCERATIVE COLITIS-ASSOCIATED COLORECTAL DYSPLASIA
Patients suffering from inflammatory bowel diseases (IBD), such as Ulcerative Colitis (UC) and Crohn’s disease (CD), can develop dysplasia which is a pre-
cancerous lesion of the colon or the rectum. Dysplasia can itself progress and transform into neoplasia and lead to colorectal cancer. In IBD, dysplasia can
develop on areas that are or have been affected by chronic inflammation; in this setting, the dysplasia is termed Dysplasia Associated to Inflammation
(DAI) (figure 1). Dysplasia may also develop independently of chronic inflammation and is termed Sporadic Dysplasia (DSp). Anatomopathological
diagnosis of DAI in IBD patients remains difficult, especially when tissue inflammation is present, as regenerative remodeling in the mucosae is observed
and impairs dysplasia confirmation.
▲Figure1: SCENIC international consensus for classificationofdysplasia in the contextof IBD (Laine L.
et al, Gastroenterology 2015). (A) polypoid pedunculated lesion, (B) polypoid sessile lesion, (C)
nonpolypoidsuperficialelevatedlesion, (D)nonpolypoidflat lesionand(E)nonpolypoiddepressedlesion.
CLINICAL CONTEXT
Pilot STUDY IN UC
We performed a pilot experiment on 15 Formalin-Fixed, Paraffin-Embedded (FFPE) samples isolated
from 5 cases of UC patients with DAI (table 1). Samples were treated following the workflow illustrated
in figure 2. We compared the proteomes of the dysplastic (DAI), the inflammatory (I) and the normal
(NL) tissues of each patient.
Proteomics:
Out of 985 quantified proteins, 7 were significantly more abundant in dysplastic tissues (table 2).
Table 2: proteins found significant in
Dysplastic vs Inflammatory tissues.
Proteins quantified only in the dysplastic
group (“DAI only”) and protein quantified
in both groups significantly more abundant





The protein is also called Na-K-2Cl co-transporter 1 (NKCC1) due to its function as transporter of 1 Na+, 1 K+ and 2
Cl- into the cell. It is involved in ionic balance and cell volume regulation [1] and is influenced by physical, hormonal,
signaling and cytokines factors. It is implicated in T cells migration via WNK1-OXSR1/STK39-SLC12A2. [2] In cancer :
it is 3 times more abundant in colorectal cancer than in normal tissue. [3] In lung adenocarcinoma, its increase is
correlated to more advance and aggressive lesions. [4] In gastric adenocarcinoma, its is associated with poor tumor
differentiation. [5] In human glioma cells, its inhibition induces reduction of migration and invasion. [6]
Immunohistochemistry forSLC12A2distribution inUCpatients samplesandcomparisontoproteomicresults:
IHC evaluation included 11 UC-DAI paired samples: I (n=9) and/or NL (n=9) tissues. Staining
intensity scale used ranges from 0 to 4 (0 = none, 1 = low, 2 = medium, 3 = high and 4 = very high).
SLC12A2 was more intense in dysplasia in both IHC and proteomics (figure 3AB). Results show that
SLC12A2 staining score is more intense in dysplastic than in inflammatory (crypts: p=0.002,
bordering epithelium: p=0.0001) and normal tissues (crypts: p=0.001, bordering epithelium:
p<0.0001) (figure 3B). SLC12A2 staining in the DAI tissue allows clear delimitation of the dysplastic
region from surrounding inflammatory tissue (see red doted line in figure 3E).
2
3 Characterisation of SLC12A2 in dysplasia and adenocarcinoma in the AOM/DSS mouse model:
C57Bl/6J mice were injected intraperitoneally with the carcinogen agent Azoxymethane (AOM) diluted in
PBS. Chronic inflammation was induced by 3 cycles of 5 days of Dextran Sulfate Sodium (DSS) 2% in their
drinking water. Mice were euthanized at different time points (see figure 4B for exact number of mice per
time point). Colon and rectum were used as FFPE material. Classification of all tissues and lesions was
established by a trained anatomopathologist specialized in gastroenterology (figure 4).
▲ Figure 4: AOM/DSS mouse model. (A) Schematic representation of the mouse model with AOM and DSS treatment cycles. (B) Mice were euthanized at days
15, 29, 34, 50, 55, 70 and 80 (n=6, 6, 6, 6, 6, 7, and 5 respectively). Mice (n=6) were treated with PBS and sacrificed at day 90 as controls. Each point represent
one lesion (see color code on figure 4C). (C) Number of samples obtained for each type of tissue., with N = normal, I = inflammation, LGD = low grade dysplasia,
HGD = high grade dysplasia and ADC = adenocarcinoma.
Evaluation of SLC12A2 distribution in colonic tissues of the AOM/DSS mouse model:
IHC staining intensity scale ranges from 0 to 4 as in UC patients. Staining intensity score of SLC12A2 was
significantly more important in dysplastic lesions (n=52) than in inflammatory (I) (n=30) and in normal (N
(PBS)) tissues (n=6). IHC scores were significantly increased in advanced lesions HGD (n=12) and ADC (n=6)
compared to LGD (n=39) (figure 5).
▲ Figure 2: proteomic experiment workflow. (1) Zones of interest were collected by Laser-
Capture Microdissection. (2) Samples were submitted to antigen retrieval for a downstream
two-step trypsin digestion. (Longuespée R. et al., Methods 2016) (3) The peptide mixtures were
analysed after separation by Ultra Performance Liquid Chromatography in two dimensions, by
an Hybrid Quadrupole-Orbitrap mass spectrometer. (4) Raw data were treated using the
MaxQuant software (Cox J., Mann M., Nat Biothechnol, 2008) and the differential analysis was
performedwithPerseussoftware(TyanovaS.etal,NatMethods,2016).
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▲ Table 1: A clinical data of the patients included in the proteomic
pilot experiment and in human immunohistochemistry.
SLC12A2 could be a potential marker of DAI in UC as being able to identify dysplasia and neoplasia from surrounding tissues with inflammation. SLC12A2 requires proper validation to evaluate its power as a specific IHC marker
that could be used to clarify difficult cases diagnosed as “indefinite for dysplasia”.
 7 proteins were found more abundant in DAI than in I paired tissues by differential label free proteomics
 SLC12A2 was only quantified in the DAI group by proteomics
 IHC of SLC12A2 in human UC-DAI paired samples confirmed our proteomic results
 In UC, staining of SLC12A2 was significantly more intense in DAI than in I and N paired tissues
 In UC, staining of SLC12A2 allowed delimitation of DAI lesion from the surrounding I tissue
 SLC12A2 detected by IHC showed an association with dysplasia and neoplasia in CAC mouse model
 HGD and LGD tissues showed a significant higher staining of SLC12A2 than LGD lesions of the CAC mouse model
Figure 3: proteomic and IHC
results for SLC12A2 on human UC
tissues. (A) Dot plot of proteomic
results. Each patient is represented
by a different colour. (B) Dot plot
illustrating IHC results for the 3
groups (N, I and DAI). Relevant
statistical tests were applied
(p<0.05) (bord. epith. = bordering
epithelium). (C,D,E) Representative
pictures of SLC12A2 IHC score in N
(C), I (D) and DAI (E) tissues of the
same patient (green patient).
Magnification 2X and 10X. conclusions
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▲ Figure 5: IHC results for SLC12A2
on mice tissues. (A) Dot plot of
staining intensity score for I, LGD, HGD,
ADC and N (PBS) tissues. Mann-
Whitney test was applied (p<0.05).
(B,C,D,E,F) Representative pictures of
SLC12A2 IHC score in N (PBS) (B), I (C),
LGD (D), HGD (E) and ADC (F).
Magnification 10X.
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◀
Research strategy: we performed a proteomic pilot study on 5 UC cases, including paired samples. Some results were confirmed by immunohistochemistry (IHC) on a higher number of
patients. Finally, mouse model of colitis-associated cancer (CAC) was used to investigate one potential biomarker highlighted by proteomics to evaluate its distribution in different lesion
types covering inflammation, DAI and adenocarcinoma.
